Rhizen Pharmaceuticals S.A. to present preclinical data of their first-in-class inflammation assets, RP6503 and RP3128 for treatment of various respiratory diseases La Chaux-de-Fonds, Switzerland, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces data for their lead first-in-class inflammation/auto-immune assets, RP6503 and RP3128 in...

Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013 La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the...